Acrodermatitis chronica atrophicans digital illustration

Acrodermatitis chronica atrophicans Save


ICD-10 code: L90.4

Disease category: L90: Atrophic disorders of skin

Understanding Acrodermatitis Chronica Atrophicans

Acrodermatitis chronica atrophicans (ACA) is a rare skin disorder that primarily affects the extremities, such as the hands and feet. It is a late manifestation of Lyme disease and is caused by the bacterium Borrelia burgdorferi. ACA is typically observed in regions where Lyme disease is endemic, such as Europe.

Here are a few key points to help you understand this condition:

  1. Progressive Skin Changes: ACA is characterized by progressive skin changes that occur over a prolonged period. Initially, patients may notice a reddish-blue discoloration on the skin, most commonly on the hands or feet. Over time, the affected areas may become swollen, thin, and atrophic, leading to a wrinkled appearance.
  2. Neurological Symptoms: In addition to skin changes, ACA can also present with neurological symptoms. Patients may experience tingling, numbness, or shooting pains in the affected areas. These symptoms can significantly impact a person's quality of life and daily activities.
  3. Diagnosis: Healthcare professionals use a combination of clinical examination, patient history, and laboratory tests to diagnose ACA. A skin biopsy may be performed to confirm the presence of Borrelia burgdorferi. It is crucial to differentiate ACA from other skin disorders to ensure appropriate treatment.
  4. Prevention: Preventing ACA involves taking steps to prevent Lyme disease. Avoiding tick-infested areas, using protective clothing, and applying insect repellents can reduce the risk of tick bites. Prompt removal of ticks and seeking medical attention if symptoms of Lyme disease develop are essential preventive measures.
  5. Management and Prognosis: Unfortunately, there is no specific treatment for ACA mentioned in this article. However, it is important to note that early diagnosis and appropriate treatment for Lyme disease can help prevent the development of ACA. Managing the symptoms and providing supportive care are crucial for patients with ACA.

In conclusion, acrodermatitis chronica atrophicans is a rare skin disorder that occurs as a late manifestation of Lyme disease. It primarily affects the extremities and is characterized by progressive skin changes and possible neurological symptoms. Timely diagnosis and treatment of Lyme disease are essential to prevent the development of ACA. If you suspect you may have ACA, it is important to consult with a healthcare professional for an accurate diagnosis and appropriate management.

Treatment of Acrodermatitis chronica atrophicans:

Treatment Options for Acrodermatitis Chronica Atrophicans

Acrodermatitis chronica atrophicans (ACA) is a rare skin disorder that primarily affects the extremities. It is characterized by progressive atrophy (thinning) of the skin, leading to various symptoms such as redness, swelling, and discoloration. If you have been diagnosed with ACA, it's essential to explore the available tr...

To see full information about treatment please Sign up or Log in